மருத்துவ புற்றுநோயியல் ஆண்டு சந்தித்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மருத்துவ புற்றுநோயியல் ஆண்டு சந்தித்தல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மருத்துவ புற்றுநோயியல் ஆண்டு சந்தித்தல் Today - Breaking & Trending Today

IMBRUVICA® Plus VENCLEXTA®/VENCLYXTO® Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia Phase 3 GLOW Study


ABBVie today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® plus VENCLEXTA ® VENCLYXTO ® versus chlorambucil plus obinutuzumab for first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had active disease requiring treatment per the International Workshop on CLL criteria. The study met its primary …
ABBVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® (ibrutinib) plus VENCLEXTA ® VENCLYXTO ® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab (C+O) for first-line treatment in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had active disease requiring treatment per the International Workshop on CLL (iwCLL) criteria. The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent re ....

United States , Rheinland Pfalz , Noord Holland , Venclyxto Sm , Mohamed Zaki , Arnon Kater , National Cancer Institute , Janssen Biotech Inc , Abbvie Company , American Society Of Clinical Oncology Annual Meeting , University Of Amsterdam Faculty Medicine , International Workshop , Abbvie Inc , Abbvie Deutschland Gmbh Co , National Comprehensive Cancer Network , Exchange Commission , Roche Group , Amsterdam Faculty , Clinical Oncology Annual Meeting , Independent Review , Janssen Biotech , Breakthrough Therapy Designations , Breakthrough Therapy Designation , Important Side Effect Information , Patient Information , Important Safety Information ,